Hims & Hers Health (NYSE:HIMS) Given New $16.50 Price Target at Citigroup

Hims & Hers Health (NYSE:HIMS) had its price target reduced by Citigroup from $30.00 to $16.50 in a report published on Monday,Benzinga reports. Citigroup currently has a sell rating on the stock.

HIMS has been the topic of several other reports. KeyCorp began coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Barclays began coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target on the stock. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Finally, Evercore initiated coverage on Hims & Hers Health in a report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $39.96.

Hims & Hers Health Trading Down 16.0%

HIMS stock opened at $19.33 on Monday. Hims & Hers Health has a 52 week low of $16.35 and a 52 week high of $72.98. The company has a market cap of $4.40 billion, a price-to-earnings ratio of 35.80, a PEG ratio of 3.79 and a beta of 2.43. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The business has a fifty day simple moving average of $32.60 and a 200-day simple moving average of $43.05.

Hims & Hers Health declared that its Board of Directors has authorized a stock repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Activity

In other news, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the sale, the chief operating officer directly owned 305,161 shares in the company, valued at $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total value of $275,092.78. Following the sale, the chief financial officer directly owned 91,617 shares in the company, valued at approximately $2,779,659.78. The trade was a 9.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 129,337 shares of company stock worth $4,651,648 over the last three months. 17.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently bought and sold shares of HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the first quarter worth approximately $30,000. Janney Montgomery Scott LLC increased its stake in shares of Hims & Hers Health by 15.1% in the second quarter. Janney Montgomery Scott LLC now owns 10,019 shares of the company’s stock worth $499,000 after buying an additional 1,311 shares during the last quarter. Truist Financial Corp raised its holdings in Hims & Hers Health by 20.7% in the second quarter. Truist Financial Corp now owns 9,643 shares of the company’s stock valued at $481,000 after acquiring an additional 1,656 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its stake in Hims & Hers Health by 2.2% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 38,000 shares of the company’s stock valued at $1,894,000 after acquiring an additional 800 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Some investors and analysts argue the market has overreacted: HIMS is not a pure GLP‑1 company, management says the oral Wegovy was pulled, and estimates (e.g., ~30% of 2025 revenue from weight‑loss) imply the business still has diversified exposure to preventative care and platform growth. Hims & Hers Health: Don’t Fall For The Hysteria
• Neutral Sentiment: Hims announced it will stop offering the compounded semaglutide pill after the FDA signaled tighter control over compounded GLP‑1 ingredients — this removes a near‑term revenue initiative but also reduces ongoing regulatory exposure from that specific product. Hims & Hers drops plan for knockoff of Novo Nordisk’s new Wegovy weight loss pill
• Negative Sentiment: Novo Nordisk filed a patent‑infringement lawsuit seeking to block HIMS from selling compounded versions of semaglutide and to recover damages — this escalates legal risk and could lead to injunctions or settlement costs. Novo Nordisk sues Hims & Hers over patent infringement
• Negative Sentiment: Investor reaction has been severe: shares plunged with heavy volume to new lows, prompting multiple analyst cuts (Citigroup, TD Cowen, BofA) that trimmed price targets and ratings — increasing near‑term downside pressure. Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit
• Negative Sentiment: Plaintiff and securities firms have opened inquiries and investor lawsuits/claims are being solicited, adding potential legal and reputational costs. HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.